Related references
Note: Only part of the references are listed.Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas
Zerui Wu et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)
Targeted Inhibition of Anti-Inflammatory Regulator Nrf2 Results in Breast Cancer Retardation In Vitro and In Vivo
Venugopal R. Bovilla et al.
BIOMEDICINES (2021)
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
Alexandra McAleenan et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma
Antje Wick et al.
NEURO-ONCOLOGY (2020)
ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion
Sophie Sarah Steinhaeuser et al.
LABORATORY INVESTIGATION (2020)
Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence
Ekjot Kaur et al.
NEURO-ONCOLOGY (2020)
Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
Gi-Hoon Nam et al.
ADVANCED MATERIALS (2020)
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Seok Won Ham et al.
CELL DEATH AND DIFFERENTIATION (2019)
Brusatol, an NRF2 inhibitor for future cancer therapeutic
Sabrina J. Cai et al.
CELL AND BIOSCIENCE (2019)
Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Ruifan Ye et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells
Hai-Ming Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2018)
UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response
Mei Wang et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
Jonathan P. Evans et al.
Oncotarget (2018)
m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer
Jun Liu et al.
NATURE CELL BIOLOGY (2018)
Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies
Zheng Lu et al.
ONCOTARGET (2017)
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Myung Soo Kim et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage
Xiaohui Sun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Brusatol inhibits the response of cultured beta-cells to pro-inflammatory cytokines in vitro
Kyril Turpaev et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2
Adedamola Olayanju et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Novel Nitric Oxide-Releasing Derivatives of Brusatol as Anti-Inflammatory Agents: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies
Weibin Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Human Melanoma Cells Over-Express Extracellular Matrix 1 (ECM1) Which Is Regulated by TFAP2C
Geeta Lal et al.
PLOS ONE (2013)
Overexpression of ECM1 Contributes to Migration and Invasion in Cholangiocarcinoma Cell
G. P. Xiong et al.
NEOPLASMA (2012)
Extracellular matrix protein 1, a novel prognostic factor, is associated with metastatic potential of hepatocellular carcinoma
Hao Chen et al.
MEDICAL ONCOLOGY (2011)
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Dongmei Ren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Characterization of the osteogenic stromal cell line MN7: Identification of secreted MN7 proteins using two-dimensional polyacrylamide gel electrophoresis, western blotting, and microsequencing
E. Mathieu et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Extracellular Matrix 1 (ECM1) Expression Is a Novel Prognostic Marker for Poor Long-Term Survival in Breast Cancer: A Hospital-Based Cohort Study in Iowa
Geeta Lal et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
The extracellular matrix protein 1: Its molecular interaction and implication in tumor progression
S. Sercu et al.
CANCER INVESTIGATION (2008)
Interaction of extracellular matrix protein 1 with extracellular matrix components: ECM1 is a basement membrane protein of the skin
Sandy Sercu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Advances in neurosurgical technique in the current management of brain tumors
GE Keles et al.
SEMINARS IN ONCOLOGY (2004)
Brusatol-mediated induction of leukemic cell differentiation and G1 arrest is associated with down-regulation of c-myc
E Mata-Greenwood et al.
LEUKEMIA (2002)
Share Paper
